Pfizer's Celebrex slammed by entry of generics

Teva, Mylan and Actavis each announced celecoxib launches at strengths of  50 mg, 100 mg, 200 mg, and 400 mg, signaling the start of a stiff sales decline for the Pfizer blockbuster.


A US District court ruling in April set the stage for the generic competition to emerge as early as May, when the court negated 15 months of patent protection on Celebrex.

close

Next Article in Pharmaceutical